Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: "Josep M. Llovet" Clear advanced filters

  • Next-generation sequencing analysis and characterization of the microenvironment 'field-effect' that promotes hepatocellular carcinoma (HCC) development has revealed critical players and potential targets for chemoprevention. A biomarker-based drug development strategy is needed to improve future HCC clinical trials and therapies.

    • Augusto Villanueva
    • Josep M. Llovet
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 11, P: 73-74

  • Hepatocellular carcinoma is a difficult-to-treat cancer and, after numerous phase III trials assessing kinase inhibitors have failed to meet their end points, sorafenib is the only accepted treatment for advanced stages of the disease. Now, the trial EVOLVE-1 has shown a lack of benefit for everolimus in the second-line treatment setting.

    • Josep M. Llovet
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 11, P: 506-507

  • A large-scale comprehensive analysis of hepatocellular carcinoma (HCC) based on the integration of six distinct data platforms has pinpointed novel oncogenic processes and prognostic subgroups. These findings confirm previously identified molecular subclasses and fuel the need for a clear strategy of precision medicine in HCC.

    • Daniela Sia
    • Josep M. Llovet
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 14, P: 571-572

  • Unexpected data from new studies show that direct-acting antiviral agents might promote tumour occurrence in patients with cirrhosis, or recurrence in patients with presumed cure of hepatocellular carcinoma. In view of the potential clinical implications, this controversy calls for a thorough and expeditious consideration of the hypothetical oncogenic activity of novel HCV drugs.

    • Josep M. Llovet
    • Augusto Villanueva
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 13, P: 561-562

  • A new study proposes a modelling strategy to identify reactions, genes and metabolites relevant in hepatocellular carcinoma using in silico and in vivo analyses. The proposed genome-scale metabolic model integrates genomic and proteomic information, and points to statins, among others, as potential chemopreventive and anticancer drugs.

    • Roser Pinyol
    • Josep M. Llovet
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 11, P: 336-337

  • Liver cancer mortality has increased in the past 20 years, and estimates indicate that the global health burden of this disease will continue to grow. Advances in our knowledge of the human genome have provided a comprehensive picture of commonly mutated genes in patients with hepatocellular carcinoma (HCC). In this Review, the authors summarize the molecular concepts of progression of HCC, discuss the potential reasons for clinical trial failure, and propose new concepts of drug development.

    • Josep M. Llovet
    • Augusto Villanueva
    • Richard S. Finn
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 12, P: 408-424